BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 17414621)

  • 1. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
    Burton JD; Castillo ME; Goldenberg DM; Blumenthal RD
    Anticancer Drugs; 2007 Jun; 18(5):525-34. PubMed ID: 17414621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
    Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
    Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma.
    Eucker J; Sterz J; Krebbel H; Zavrski I; Kaiser M; Zang C; Heider U; Jakob C; Elstner E; Sezer O
    Anticancer Drugs; 2006 Aug; 17(7):763-9. PubMed ID: 16926626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
    Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
    Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro.
    Valentiner U; Carlsson M; Erttmann R; Hildebrandt H; Schumacher U
    Toxicology; 2005 Sep; 213(1-2):157-68. PubMed ID: 16009482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists.
    Lea MA; Sura M; Desbordes C
    Anticancer Res; 2004; 24(5A):2765-71. PubMed ID: 15517883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer.
    Shigeto T; Yokoyama Y; Xin B; Mizunuma H
    Oncol Rep; 2007 Oct; 18(4):833-40. PubMed ID: 17786343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma.
    Takashima T; Fujiwara Y; Hamaguchi M; Sasaki E; Tominaga K; Watanabe T; Oshitani N; Higuchi K; Arakawa T
    Oncol Rep; 2005 Apr; 13(4):601-6. PubMed ID: 15756430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells.
    Aouali N; Palissot V; El-Khoury V; Moussay E; Janji B; Pierson S; Brons NH; Kellner L; Bosseler M; Van Moer K; Berchem G
    Br J Haematol; 2009 Dec; 147(5):662-71. PubMed ID: 19793255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?
    Han S; Roman J
    Anticancer Drugs; 2007 Mar; 18(3):237-44. PubMed ID: 17264754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
    Nagata D; Yoshihiro H; Nakanishi M; Naruyama H; Okada S; Ando R; Tozawa K; Kohri K
    Cancer Detect Prev; 2008; 32(3):259-66. PubMed ID: 18789607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth.
    Li M; Lee TW; Mok TS; Warner TD; Yim AP; Chen GG
    J Cell Biochem; 2005 Nov; 96(4):760-74. PubMed ID: 16149072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells.
    Yoshimura R; Matsuyama M; Hase T; Tsuchida K; Kuratsukuri K; Kawahito Y; Sano H; Segawa Y; Nakatani T
    Int J Mol Med; 2003 Dec; 12(6):861-5. PubMed ID: 14612958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment.
    Grommes C; Landreth GE; Sastre M; Beck M; Feinstein DL; Jacobs AH; Schlegel U; Heneka MT
    Mol Pharmacol; 2006 Nov; 70(5):1524-33. PubMed ID: 16887936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma.
    Masuda T; Wada K; Nakajima A; Okura M; Kudo C; Kadowaki T; Kogo M; Kamisaki Y
    Clin Cancer Res; 2005 Jun; 11(11):4012-21. PubMed ID: 15930335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
    Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
    Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
    Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
    Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
    Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
    Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
    Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
    Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.